CONNECTA Therapeutics Secures EIC Funding for CTH120 Pediatric Development in Fragile X Syndrome CONNECTA Therapeutics has announced the launch of its pediatric development program for CTH120, a groundbreaking treatment for Fragile X Syndrome, supported by a €2.5M EIC grant.

CONNECTA Therapeutics Secures EIC Funding for CTH120 Pediatric Development in Fragile X Syndrome #Spain #Barcelona #Fragile_X_Syndrome #CONNECTA_Therapeutics #CTH120